Project Grant K08CA317629
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $204K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98195, USA
Similar Awards
- The National Cancer Institute awarded the University of Washington a $965,502 cooperative agreement on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a two-phase pilot and pragmatic trial evaluating human papillomavirus self-sampling for cervical cancer screening in federally qualified health centers. The STEP-2 trial will adapt and evaluate two intervention programs to integrate HPV self-sampling into FQHCs in Oregon and Washington, addressing low...
- The National Cancer Institute awarded Fred Hutchinson Cancer Center $737,945 on May 4, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop quantitative measurement tools for assessing provider and intervention characteristic determinants of evidence-based cancer care implementation. The project addresses critical gaps in implementation science by using item response theory to create flexible, tailorable quantitative measures of intervention and provider...
- The National Cancer Institute awarded the University of Washington $142,780 on January 23, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support biomedical training in careers in basic, clinical, and prevention research relevant to the National Cancer Program. The award funds research addressing antigen-low tumor escape in non-small cell lung cancer through chimeric T cell receptor (ChTCR) therapy. The project develops engineered ChTCRs that fuse a CAR single-chain variable...
- The National Cancer Institute awarded the University of Washington $149,190 on December 25, 2025, under the Cancer Research Manpower program (CFDA 93.398) to fund research elucidating the role of type 2 conventional dendritic cells in shaping anti-tumor immunity. The recipient will conduct ex vivo co-culture studies and immunological characterization to test the hypothesis that intratumoral type 2 conventional dendritic cells limit anti-tumor immunity by promoting CD8 T cell exhaustion. The work...
- The National Cancer Institute awarded the University of California, Los Angeles $446,900 on September 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to optimize geographic expansion of cervical cancer screening and treatment in remote and rural settings. The recipient will develop a scientific framework to identify optimal strategies for expanding cervical cancer screening access under resource constraints, designed to assist the Indian Health Service, the Alaska...
- The National Cancer Institute awarded the University of Washington $686,271 on May 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to support proteomics-driven analysis and robotics-enabled drug testing of microdissected tumors and their microenvironment. The funded work develops high-throughput approaches to rapidly dissect thousands of regularly-sized microdissected tumor tissues (MDTs) from single biopsies. Tumor tissue is mechanically cut into approximately...
- The National Cancer Institute awarded The Washington University $160,093 on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate perceptions and informational needs regarding prostate cancer screening among screening-eligible men, with particular attention to racial disparities. The research addresses how men perceive the harms and benefits of prostate-specific antigen (PSA)-based screening, especially in the context of risk-stratified screening...
- The National Cancer Institute awarded the University of Washington $641,632 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to conduct functional and mechanistic interrogation of kinase complexes and their ligandability. The recipient will use the KICCA approach to study kinase-protein interactions in native cells and tissues across ten cell signaling pathways in 25 cancer cell lines and clinical samples of primary liver cancer. Work includes applying chemical labeling...
- The National Cancer Institute awarded the University of Washington $405,244 on August 13, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and optimize immunopixelseq, a cost-effective spatial immunosequencing platform for precision immuno-oncology research. Immunopixelseq uses 0.6-micrometer-resolution polony gel stamping to produce low-cost arrays compatible with standard Illumina short-read sequencing, enabling spatial co-profiling of whole-tissue...
- The National Cancer Institute awarded The Washington University $425,088 on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to evaluate the delivery and quality of lung cancer care among older adults enrolled in Medicare Advantage versus traditional Medicare. The research examines disparities in lung cancer screening, diagnosis, treatment patterns, and clinical outcomes across these two insurance programs. The project compares guideline-concordant treatment...